APO Research
Talk to an analyst

APO RESEARCH · REPORT

COPD Medicine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global COPD Medicine Market Analysis and Forecast 2026-2032

2 January 2026190 pages

Choose your research edition.

Industry ResearchCOPD Medicine Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal COPD Medicine Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal COPD Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal COPD Medicine Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal COPD Medicine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global COPD Medicine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for COPD Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for COPD Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for COPD Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for COPD Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of COPD Medicine include GSK, Teva, Novartis, Merck, Roche, AstraZeneca, Viatris, Vertex and Sumitomo Dainippon, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for COPD Medicine, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of COPD Medicine, also provides the revenue of main regions and countries. Of the upcoming market potential for COPD Medicine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the COPD Medicine revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global COPD Medicine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for COPD Medicine revenue, projected growth trends, production technology, application and end-user industry.

COPD Medicine Segment by Company

GSK

Teva

Novartis

Merck

Roche

AstraZeneca

Viatris

Vertex

Sumitomo Dainippon

Chiesi

Boehringer Ingelheim

Beximco

COPD Medicine Segment by Type

Inhalable & Nasal Spray

Oral

Others

COPD Medicine Segment by Application

Hospital

Drugs Store

COPD Medicine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global COPD Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of COPD Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of COPD Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of COPD Medicine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of COPD Medicine company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, COPD Medicine revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global COPD Medicine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Inhalable & Nasal Spray Major Player Table 3. Oral Major Player Table 4. Others Major Player Table 5. Global COPD Medicine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Major Player Table 7. Drugs Store Major Player Table 8. COPD Medicine Industry Trends Table 9. COPD Medicine Industry Drivers Table 10. COPD Medicine Industry Opportunities and Challenges Table 11. COPD Medicine Industry Restraints Table 12. Global COPD Medicine Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global COPD Medicine Market Size by Region (2021-2026) & (US$ Million) Table 14. Global COPD Medicine Market Share by Region (2021-2026) Table 15. Global COPD Medicine Market Size by Region (2027-2032) & (US$ Million) Table 16. Global COPD Medicine Market Share by Region (2027-2032) Table 17. Global COPD Medicine Revenue by Players (US$ Million) & (2021-2026) Table 18. Global COPD Medicine Revenue Market Share by Players (2021-2026) Table 19. Global COPD Medicine Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global COPD Medicine Key Players Headquarters & Area Served Table 21. Global COPD Medicine Players, Product Type & Application Table 22. Global COPD Medicine Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global COPD Medicine by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global COPD Medicine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global COPD Medicine Revenue by Type (2021-2026) & (US$ Million) Table 27. Global COPD Medicine Revenue by Type (2027-2032) & (US$ Million) Table 28. Global COPD Medicine Revenue Market Share by Type (2021-2026) Table 29. Global COPD Medicine Revenue Market Share by Type (2027-2032) Table 30. Global COPD Medicine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global COPD Medicine Revenue by Application (2021-2026) & (US$ Million) Table 32. Global COPD Medicine Revenue by Application (2027-2032) & (US$ Million) Table 33. Global COPD Medicine Revenue Market Share by Application (2021-2026) Table 34. Global COPD Medicine Revenue Market Share by Application (2027-2032) Table 35. GSK Company Information Table 36. GSK Business Overview Table 37. GSK COPD Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. GSK COPD Medicine Product Portfolio Table 39. GSK Recent Development Table 40. Teva Company Information Table 41. Teva Business Overview Table 42. Teva COPD Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Teva COPD Medicine Product Portfolio Table 44. Teva Recent Development Table 45. Novartis Company Information Table 46. Novartis Business Overview Table 47. Novartis COPD Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Novartis COPD Medicine Product Portfolio Table 49. Novartis Recent Development Table 50. Merck Company Information Table 51. Merck Business Overview Table 52. Merck COPD Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Merck COPD Medicine Product Portfolio Table 54. Merck Recent Development Table 55. Roche Company Information Table 56. Roche Business Overview Table 57. Roche COPD Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Roche COPD Medicine Product Portfolio Table 59. Roche Recent Development Table 60. AstraZeneca Company Information Table 61. AstraZeneca Business Overview Table 62. AstraZeneca COPD Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. AstraZeneca COPD Medicine Product Portfolio Table 64. AstraZeneca Recent Development Table 65. Viatris Company Information Table 66. Viatris Business Overview Table 67. Viatris COPD Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Viatris COPD Medicine Product Portfolio Table 69. Viatris Recent Development Table 70. Vertex Company Information Table 71. Vertex Business Overview Table 72. Vertex COPD Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Vertex COPD Medicine Product Portfolio Table 74. Vertex Recent Development Table 75. Sumitomo Dainippon Company Information Table 76. Sumitomo Dainippon Business Overview Table 77. Sumitomo Dainippon COPD Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Sumitomo Dainippon COPD Medicine Product Portfolio Table 79. Sumitomo Dainippon Recent Development Table 80. Chiesi Company Information Table 81. Chiesi Business Overview Table 82. Chiesi COPD Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Chiesi COPD Medicine Product Portfolio Table 84. Chiesi Recent Development Table 85. Boehringer Ingelheim Company Information Table 86. Boehringer Ingelheim Business Overview Table 87. Boehringer Ingelheim COPD Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Boehringer Ingelheim COPD Medicine Product Portfolio Table 89. Boehringer Ingelheim Recent Development Table 90. Beximco Company Information Table 91. Beximco Business Overview Table 92. Beximco COPD Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Beximco COPD Medicine Product Portfolio Table 94. Beximco Recent Development Table 95. North America COPD Medicine Revenue by Type (2021-2026) & (US$ Million) Table 96. North America COPD Medicine Revenue by Type (2027-2032) & (US$ Million) Table 97. North America COPD Medicine Revenue by Application (2021-2026) & (US$ Million) Table 98. North America COPD Medicine Revenue by Application (2027-2032) & (US$ Million) Table 99. North America COPD Medicine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. North America COPD Medicine Revenue by Country (2021-2026) & (US$ Million) Table 101. North America COPD Medicine Revenue by Country (US$ Million) & (2027-2032) Table 102. Europe COPD Medicine Revenue by Type (2021-2026) & (US$ Million) Table 103. Europe COPD Medicine Revenue by Type (2027-2032) & (US$ Million) Table 104. Europe COPD Medicine Revenue by Application (2021-2026) & (US$ Million) Table 105. Europe COPD Medicine Revenue by Application (2027-2032) & (US$ Million) Table 106. Europe COPD Medicine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. Europe COPD Medicine Revenue by Country (2021-2026) & (US$ Million) Table 108. Europe COPD Medicine Revenue by Country (US$ Million) & (2027-2032) Table 109. China COPD Medicine Revenue by Type (2021-2026) & (US$ Million) Table 110. China COPD Medicine Revenue by Type (2027-2032) & (US$ Million) Table 111. China COPD Medicine Revenue by Application (2021-2026) & (US$ Million) Table 112. China COPD Medicine Revenue by Application (2027-2032) & (US$ Million) Table 113. Asia COPD Medicine Revenue by Type (2021-2026) & (US$ Million) Table 114. Asia COPD Medicine Revenue by Type (2027-2032) & (US$ Million) Table 115. Asia COPD Medicine Revenue by Application (2021-2026) & (US$ Million) Table 116. Asia COPD Medicine Revenue by Application (2027-2032) & (US$ Million) Table 117. Asia COPD Medicine Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 118. Asia COPD Medicine Revenue by Region (US$ Million) & (2021-2026) Table 119. Asia COPD Medicine Revenue by Region (US$ Million) & (2027-2032) Table 120. SAMEA COPD Medicine Revenue by Type (2021-2026) & (US$ Million) Table 121. SAMEA COPD Medicine Revenue by Type (2027-2032) & (US$ Million) Table 122. SAMEA COPD Medicine Revenue by Application (2021-2026) & (US$ Million) Table 123. SAMEA COPD Medicine Revenue by Application (2027-2032) & (US$ Million) Table 124. SAMEA COPD Medicine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 125. SAMEA COPD Medicine Revenue by Country (2021-2026) & (US$ Million) Table 126. SAMEA COPD Medicine Revenue by Country (US$ Million) & (2027-2032) Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. COPD Medicine Image Figure 2. Global COPD Medicine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global COPD Medicine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Inhalable & Nasal Spray Image Figure 5. Oral Image Figure 6. Others Image Figure 7. Global COPD Medicine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global COPD Medicine Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Image Figure 10. Drugs Store Image Figure 11. Global COPD Medicine Market Size (US$ Million) & (2021-2032) Figure 12. Global COPD Medicine Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global COPD Medicine Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global COPD Medicine Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global COPD Medicine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global COPD Medicine Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global COPD Medicine Revenue Market Share by Type (2021-2032) Figure 19. Global COPD Medicine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global COPD Medicine Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global COPD Medicine Revenue Market Share by Application (2021-2032) Figure 22. North America COPD Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America COPD Medicine Revenue Share by Type (2021-2032) Figure 24. North America COPD Medicine Revenue Share by Application (2021-2032) Figure 25. North America COPD Medicine Revenue Share by Country (2021-2032) Figure 26. United States COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe COPD Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe COPD Medicine Revenue Share by Type (2021-2032) Figure 31. Europe COPD Medicine Revenue Share by Application (2021-2032) Figure 32. Europe COPD Medicine Revenue Share by Country (2021-2032) Figure 33. Germany COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China COPD Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China COPD Medicine Revenue Share by Type (2021-2032) Figure 43. China COPD Medicine Revenue Share by Application (2021-2032) Figure 44. Asia COPD Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia COPD Medicine Revenue Share by Type (2021-2032) Figure 46. Asia COPD Medicine Revenue Share by Application (2021-2032) Figure 47. Asia COPD Medicine Revenue Share by Region (2021-2032) Figure 48. Japan COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA COPD Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA COPD Medicine Revenue Share by Type (2021-2032) Figure 56. SAMEA COPD Medicine Revenue Share by Application (2021-2032) Figure 57. SAMEA COPD Medicine Revenue Share by Country (2021-2032) Figure 58. Brazil COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt COPD Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Inhalable & Nasal Spray
  • Oral
  • Others
Applications
  • Hospital
  • Drugs Store
Companies covered
  • GSK
  • Teva
  • Novartis
  • Merck
  • Roche
  • AstraZeneca
  • Viatris
  • Vertex
  • Sumitomo Dainippon
  • Chiesi
  • Boehringer Ingelheim
  • Beximco

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 COPD Medicine Market by Type
  3. 1.2.1 Global COPD Medicine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Inhalable & Nasal Spray
  5. 1.2.3 Oral
  6. 1.2.4 Others
  7. 1.3 COPD Medicine Market by Application
  8. 1.3.1 Global COPD Medicine Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Drugs Store
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 COPD Medicine Market Dynamics
  1. 2.1 COPD Medicine Industry Trends
  2. 2.2 COPD Medicine Industry Drivers
  3. 2.3 COPD Medicine Industry Opportunities and Challenges
  4. 2.4 COPD Medicine Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global COPD Medicine Market Perspective (2021-2032)
  2. 3.2 Global COPD Medicine Growth Trends by Region
  3. 3.2.1 Global COPD Medicine Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global COPD Medicine Market Size by Region (2021-2026)
  5. 3.2.3 Global COPD Medicine Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global COPD Medicine Revenue by Players
  2. 4.1.1 Global COPD Medicine Revenue by Players (2021-2026)
  3. 4.1.2 Global COPD Medicine Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global COPD Medicine Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global COPD Medicine Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global COPD Medicine Key Players Headquarters & Area Served
  7. 4.4 Global COPD Medicine Players, Product Type & Application
  8. 4.5 Global COPD Medicine Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global COPD Medicine Market CR5 and HHI
  11. 4.6.3 2025 COPD Medicine Tier 1, Tier 2, and Tier 3
5 COPD Medicine Market Size by Type
  1. 5.1 Global COPD Medicine Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global COPD Medicine Revenue by Type (2021-2032)
  3. 5.3 Global COPD Medicine Revenue Market Share by Type (2021-2032)
6 COPD Medicine Market Size by Application
  1. 6.1 Global COPD Medicine Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global COPD Medicine Revenue by Application (2021-2032)
  3. 6.3 Global COPD Medicine Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 GSK
  2. 7.1.1 GSK Company Information
  3. 7.1.2 GSK Business Overview
  4. 7.1.3 GSK COPD Medicine Revenue and Gross Margin (2021-2026)
  5. 7.1.4 GSK COPD Medicine Product Portfolio
  6. 7.1.5 GSK Recent Developments
  7. 7.2 Teva
  8. 7.2.1 Teva Company Information
  9. 7.2.2 Teva Business Overview
  10. 7.2.3 Teva COPD Medicine Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Teva COPD Medicine Product Portfolio
  12. 7.2.5 Teva Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis COPD Medicine Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Novartis COPD Medicine Product Portfolio
  18. 7.3.5 Novartis Recent Developments
  19. 7.4 Merck
  20. 7.4.1 Merck Company Information
  21. 7.4.2 Merck Business Overview
  22. 7.4.3 Merck COPD Medicine Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Merck COPD Medicine Product Portfolio
  24. 7.4.5 Merck Recent Developments
  25. 7.5 Roche
  26. 7.5.1 Roche Company Information
  27. 7.5.2 Roche Business Overview
  28. 7.5.3 Roche COPD Medicine Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Roche COPD Medicine Product Portfolio
  30. 7.5.5 Roche Recent Developments
  31. 7.6 AstraZeneca
  32. 7.6.1 AstraZeneca Company Information
  33. 7.6.2 AstraZeneca Business Overview
  34. 7.6.3 AstraZeneca COPD Medicine Revenue and Gross Margin (2021-2026)
  35. 7.6.4 AstraZeneca COPD Medicine Product Portfolio
  36. 7.6.5 AstraZeneca Recent Developments
  37. 7.7 Viatris
  38. 7.7.1 Viatris Company Information
  39. 7.7.2 Viatris Business Overview
  40. 7.7.3 Viatris COPD Medicine Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Viatris COPD Medicine Product Portfolio
  42. 7.7.5 Viatris Recent Developments
  43. 7.8 Vertex
  44. 7.8.1 Vertex Company Information
  45. 7.8.2 Vertex Business Overview
  46. 7.8.3 Vertex COPD Medicine Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Vertex COPD Medicine Product Portfolio
  48. 7.8.5 Vertex Recent Developments
  49. 7.9 Sumitomo Dainippon
  50. 7.9.1 Sumitomo Dainippon Company Information
  51. 7.9.2 Sumitomo Dainippon Business Overview
  52. 7.9.3 Sumitomo Dainippon COPD Medicine Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Sumitomo Dainippon COPD Medicine Product Portfolio
  54. 7.9.5 Sumitomo Dainippon Recent Developments
  55. 7.10 Chiesi
  56. 7.10.1 Chiesi Company Information
  57. 7.10.2 Chiesi Business Overview
  58. 7.10.3 Chiesi COPD Medicine Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Chiesi COPD Medicine Product Portfolio
  60. 7.10.5 Chiesi Recent Developments
  61. 7.11 Boehringer Ingelheim
  62. 7.11.1 Boehringer Ingelheim Company Information
  63. 7.11.2 Boehringer Ingelheim Business Overview
  64. 7.11.3 Boehringer Ingelheim COPD Medicine Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Boehringer Ingelheim COPD Medicine Product Portfolio
  66. 7.11.5 Boehringer Ingelheim Recent Developments
  67. 7.12 Beximco
  68. 7.12.1 Beximco Company Information
  69. 7.12.2 Beximco Business Overview
  70. 7.12.3 Beximco COPD Medicine Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Beximco COPD Medicine Product Portfolio
  72. 7.12.5 Beximco Recent Developments
8 North America
  1. 8.1 North America COPD Medicine Revenue (2021-2032)
  2. 8.2 North America COPD Medicine Revenue by Type (2021-2032)
  3. 8.2.1 North America COPD Medicine Revenue by Type (2021-2026)
  4. 8.2.2 North America COPD Medicine Revenue by Type (2027-2032)
  5. 8.3 North America COPD Medicine Revenue Share by Type (2021-2032)
  6. 8.4 North America COPD Medicine Revenue by Application (2021-2032)
  7. 8.4.1 North America COPD Medicine Revenue by Application (2021-2026)
  8. 8.4.2 North America COPD Medicine Revenue by Application (2027-2032)
  9. 8.5 North America COPD Medicine Revenue Share by Application (2021-2032)
  10. 8.6 North America COPD Medicine Revenue by Country
  11. 8.6.1 North America COPD Medicine Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America COPD Medicine Revenue by Country (2021-2026)
  13. 8.6.3 North America COPD Medicine Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe COPD Medicine Revenue (2021-2032)
  2. 9.2 Europe COPD Medicine Revenue by Type (2021-2032)
  3. 9.2.1 Europe COPD Medicine Revenue by Type (2021-2026)
  4. 9.2.2 Europe COPD Medicine Revenue by Type (2027-2032)
  5. 9.3 Europe COPD Medicine Revenue Share by Type (2021-2032)
  6. 9.4 Europe COPD Medicine Revenue by Application (2021-2032)
  7. 9.4.1 Europe COPD Medicine Revenue by Application (2021-2026)
  8. 9.4.2 Europe COPD Medicine Revenue by Application (2027-2032)
  9. 9.5 Europe COPD Medicine Revenue Share by Application (2021-2032)
  10. 9.6 Europe COPD Medicine Revenue by Country
  11. 9.6.1 Europe COPD Medicine Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe COPD Medicine Revenue by Country (2021-2026)
  13. 9.6.3 Europe COPD Medicine Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China COPD Medicine Revenue (2021-2032)
  2. 10.2 China COPD Medicine Revenue by Type (2021-2032)
  3. 10.2.1 China COPD Medicine Revenue by Type (2021-2026)
  4. 10.2.2 China COPD Medicine Revenue by Type (2027-2032)
  5. 10.3 China COPD Medicine Revenue Share by Type (2021-2032)
  6. 10.4 China COPD Medicine Revenue by Application (2021-2032)
  7. 10.4.1 China COPD Medicine Revenue by Application (2021-2026)
  8. 10.4.2 China COPD Medicine Revenue by Application (2027-2032)
  9. 10.5 China COPD Medicine Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia COPD Medicine Revenue (2021-2032)
  2. 11.2 Asia COPD Medicine Revenue by Type (2021-2032)
  3. 11.2.1 Asia COPD Medicine Revenue by Type (2021-2026)
  4. 11.2.2 Asia COPD Medicine Revenue by Type (2027-2032)
  5. 11.3 Asia COPD Medicine Revenue Share by Type (2021-2032)
  6. 11.4 Asia COPD Medicine Revenue by Application (2021-2032)
  7. 11.4.1 Asia COPD Medicine Revenue by Application (2021-2026)
  8. 11.4.2 Asia COPD Medicine Revenue by Application (2027-2032)
  9. 11.5 Asia COPD Medicine Revenue Share by Application (2021-2032)
  10. 11.6 Asia COPD Medicine Revenue by Country
  11. 11.6.1 Asia COPD Medicine Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia COPD Medicine Revenue by Country (2021-2026)
  13. 11.6.3 Asia COPD Medicine Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA COPD Medicine Revenue (2021-2032)
  2. 12.2 SAMEA COPD Medicine Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA COPD Medicine Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA COPD Medicine Revenue by Type (2027-2032)
  5. 12.3 SAMEA COPD Medicine Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA COPD Medicine Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA COPD Medicine Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA COPD Medicine Revenue by Application (2027-2032)
  9. 12.5 SAMEA COPD Medicine Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA COPD Medicine Revenue by Country
  11. 12.6.1 SAMEA COPD Medicine Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA COPD Medicine Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA COPD Medicine Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst